TL;DR
This study identifies a novel molecular stratification for sarcoma based on lipid metabolism-associated genes, leading to a prognostic model that predicts patient outcomes. This model highlights squalene epoxidase (SQLE) as a potential therapeutic target, with its inhibition showing promise in suppressing sarcoma cell growth.
What Problem Does This Paper Address?
Sarcomas, a diverse group of connective tissue cancers, remain challenging to treat due to their heterogeneity and tendency to metastasize. While conventional therapies exist, many patients still face poor prognoses. The paper addresses the need for more precise diagnostic and therapeutic strategies by investigating the role of lipid metabolism in sarcoma. Altered lipid metabolism is a known hallmark of cancer, influencing tumor growth, recurrence, and drug resistance, yet its specific role and potential as a therapeutic target in sarcoma have not been fully elucidated through molecular stratification.
Methods
The researchers employed a multi-pronged approach:
- Molecular Stratification: They used non-negative matrix factorization (NMF) clustering on lipid metabolism-associated genes (LMAGs) from the TCGA-SARC dataset to identify distinct patient subgroups.
- Prognostic Model Development: A Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis was used to select key LMAGs for a prognostic model, followed by multivariate Cox regression to refine it. The final model incorporated squalene epoxidase (SQLE) and tumor necrosis factor (TNF).
- Immune Microenvironment Analysis: They assessed the correlation between risk scores and immune cell infiltration using Spearman analysis and the CIBERSORT tool. Immune checkpoint gene expression and tumor mutational burden (TMB) were also analyzed.
- Drug Sensitivity Prediction: The GDSC database and the oncopredict R package were used to estimate drug sensitivity in different risk groups.
- In Vitro Validation: SQLE was experimentally targeted in sarcoma cell lines (A-673 and U2OS) through knockdown and treatment with the SQLE inhibitor terbinafine to assess its impact on cell proliferation, colony formation, and apoptosis.
Datasets
The study utilized several public datasets for training and validation:
- TCGA-SARC: The Cancer Genome Atlas Sarcoma cohort, used for initial molecular stratification and prognostic model development.
- TARGET-OS: Therapeutically Applicable Research to Generate Effective Treatments Osteosarcoma dataset, used for external validation.
- GEO Datasets: GSE17674 and GSE63157, also used for external validation.
- CHCAMS Cohort: A local cohort of 48 sarcoma patients, used for independent validation of the prognostic model.
Key Insights and Ideas
- Lipid Metabolism as a Prognostic Indicator: The study demonstrates that genes involved in lipid metabolism can effectively stratify sarcoma patients into distinct prognostic groups. This highlights a previously underappreciated role for metabolic pathways in determining sarcoma outcomes.
- SQLE and TNF as Key Prognostic Genes: The identified prognostic model, comprising SQLE and TNF, provides a concise yet powerful tool for predicting patient survival. The opposing roles of these genes (SQLE generally associated with poor prognosis, TNF with better) offer a nuanced view of metabolic influence.
- Low-Risk Group: Immune-Rich and Immunotherapy-Responsive: Patients in the low-risk group exhibited a higher infiltration of immune cells and increased expression of immune checkpoint genes. This suggests that these patients might be more responsive to immunotherapy, offering a potential avenue for personalized treatment.
- SQLE as a Vulnerable Target: SQLE, a crucial enzyme in cholesterol biosynthesis, emerged as a significant driver of sarcoma progression. Its overexpression in high-risk patients and the observed inhibition of sarcoma cell growth upon its knockdown or inhibition by terbinafine strongly suggest it as a promising therapeutic target.
Key Results
- Prognostic Model: A novel prognostic model based on SQLE and TNF was constructed, demonstrating significant predictive power across multiple independent datasets.
- Survival Prediction: Patients in the high-risk group consistently showed shorter overall survival (OS) and progression-free survival (PFS) compared to the low-risk group. For instance, in the TCGA-SARC cohort, the p-value for OS difference between clusters was <0.001.
- Immune Infiltration: Low-risk patients showed significantly higher proportions of CD8+ T cells, M0 and M1 macrophages, monocytes, and resting dendritic cells. Immune checkpoint genes like BTLA, CTLA4, and PDL1 were also significantly upregulated in this group.
- Drug Sensitivity: The study identified potential drug sensitivities for each risk group, suggesting that low-risk patients might benefit from PI3K, HDAC, FGFR, and IGF-1R inhibitors, while high-risk patients could be more sensitive to mTOR, topoisomerase II, and CDK4/6 inhibitors.
- SQLE Inhibition: Knockdown of SQLE in sarcoma cell lines significantly inhibited cell proliferation and colony formation, while promoting apoptosis. The SQLE inhibitor terbinafine also demonstrated dose- and time-dependent inhibition of cell viability.
Limitations and Future Work
The authors acknowledge that in vivo experiments are required to further confirm the therapeutic potential of the identified targets. While the study provides a comprehensive description and improves understanding, the authors suggest that targeting lipid metabolism and cholesterol biosynthesis warrants further investigation for more robust therapeutic approaches in sarcoma. The study's findings lay the groundwork for deeper biological, diagnostic, and therapeutic exploration of sarcoma.
Summary updated